Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 20/20 | 0.78 |
| ▸ | CDK2 | P24941 | 20/20 | 0.78 |
| ▸ | CCNA1 | P78396 | 20/20 | 0.78 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.68 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.68 |
| ▸ | CDK1 | P06493 | 2/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.68 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.68 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.68 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786532 | 1.00 | CCNA2 (0.78) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6783043 | 1.00 | CCNA2 (0.78) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6788306 | 0.95 | CCNA2 (0.71) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6783369 | 0.95 | CCNA2 (0.71) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6790974 | 0.95 | CCNA2 (0.71) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6786755 | 0.95 | CCNA2 (0.71) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6790199 | 0.95 | CCNA2 (0.71) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6788496 | 0.95 | CCNA2 (0.71) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL24535015 | 0.87 | CCNA2 (0.73) | CCNA2CDK2CCNA1 | |
| SCHEMBL18285196 | 0.87 | CCNA2 (0.70) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2004-01-29 | — | — | US | disclosed |
| EP-1345909-A1 | PHENYLACETAMIDO-PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2003-09-24 | — | — | EP | disclosed |
| US-6455559-B1 | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2002-09-24 | — | — | US | disclosed |
| WO-2002048114-A1 | PHENYLACETAMIDO- PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | DCK, CCNK, CDK2 | CCNA2 120/4885CDK2 3/4885CCNA1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.